IQV

RESEARCH TRIANGLE PARK, N.C., July 08, 2026--(BUSINESS WIRE)--IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, will announce its second-quarter 2026 financial results before the market opens on Tuesday, July 28, 2026. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at: http://ir.iqvia.com. To listen to the event and view the presentation slides via webcast, join via the IQVIA Investor Relations website at: http://ir.iqvia.com. To participate in the conference call, interested parties must register in advance at: http://ir.iqvia.com. Following registration for the call, participants will receive a confirmation email containing details on how to join the conference call, including the dial-in and a unique passcode and registrant ID. At the time of the live event, registered participants can connect to the call using the information provided in the confirmation email and will be placed directly into the call. A replay of the webcast will be available approximately two hours after the conclusion of the live event. To access the webcast recording, visit: http://ir.iqvia.com. About IQVIA IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI®, advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using AI responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 93,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patie...

ICON plc ICLR is facing a classic recovery-stock test. The valuation has compressed, bookings have improved and backlog is larger. The problem is that the earnings reset is not over. Investors still have to weigh better order flow against weaker 2026 expectations, margin pressure, control remediation and leverage. ICLR trades at roughly 16.9X forward 12-month earnings. That is below its five-year median of 18.1X and below the broader Zacks Medical sector and S&P 500 multiples in the same valuation snapshot. Image Source: Zacks Investment Research The discount gives the stock a value angle, but not a clean bargain label. The $164 price target sits below the quoted stock price of $173.06, suggesting the lower multiple does not fully offset the current risk profile. The bearish case starts with management’s outlook. ICON reaffirmed 2026 revenue guidance of $7.85 billion to $8.15 billion, below the $8.25 billion generated in 2025. Adjusted earnings per share guidance of $10.00 to $11.00 also trails 2025 adjusted earnings of $12.53 per share. That makes ICLR harder to frame as an immediate recovery story, because investors are still underwriting a year of lower sales and lower earnings. The turnaround case rests on better demand indicators. Net business wins totaled $2.88 billion in the first quarter of 2026, gross bookings reached $3.26 billion, cancellations were $383 million and net book-to-bill was 1.42X. Backlog rose 4% sequentially to $22.7 billion. Management also pointed to new partnerships, including a central labs partnership with a top-five pharma customer and a midsized pharma win that displaced an incumbent large contract research organization provider. The financial benefit is expected to be more relevant to 2027 than 2026, so backlog still needs to convert into margins and earnings. IQVIA Holdings Inc. IQV is a relevant peer because it also serves life sciences customers across research, development, data and technology. Thermo Fisher Scientific Inc. TMO, through its PPD clinical research business, gives investors another comparison point for competitive dynamics in contract research. Execution risk remains elevated because ICON is not dealing only with a demand cycle. The Audit Committee investigation found improper revenue adjustments tied to clinical trial services from the third quarter of 2023 through the fourth quarter of 2024, along with err...

Durham, North Carolina-based IQVIA Holdings Inc. (IQV) provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas and internationally. Valued at a market cap of $34.6 billion, the company operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. IQV is expected to release its Q2 2026 earnings soon. Ahead of the event, analysts expect the company’s EPS to be $2.74 on a diluted basis, up 8.3% from $2.53 in the year-ago quarter. The company has exceeded Wall Street’s EPS estimates in each of its last four quarters. SanDisk Slumps 10% But BofA Stays Bullish. Here Is How to Play SanDisk Stock Here. 1 High-Probability Iron Condor Trade on Broadcom Stock to Make Now with 29% Return Potential Nasdaq Futures Slip as Chip Stocks Extend Slide, U.S. Jobs Report in Focus Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. For fiscal 2026, analysts project the company’s EPS to be $11.60, up 7.3% from $10.81 in fiscal 2025. Moreover, its EPS is expected to rise by roughly 11.8% year over year (YoY) to $12.97 in fiscal 2027. IQV stock has risen 25.6% over the past 52 weeks, rallying the S&P 500 Index’s ($SPX) 20.2% rise and the State Street Healthcare Select Sector SPDR ETF’s (XLV) 21% rise during the same time frame. On July 1, IQV stock rose 5.8% following an upgrade in its price target by Baird from $230 to $249, while coining it as a ‘Bullish Fresh Pick.’ The company is on the front lines of artificial intelligence driving the charge in the clinical trial market, which is seeing substantial investment activity. As the medical sector moves towards more AI-integrated solutions, IQV is expected to benefit from it immensely, given its favorable position in the sector. Analysts are highly optimistic about IQV, with the stock having a “Strong Buy” rating overall. Among the 21 analysts covering the stock, 16 are recommending a “Strong Buy,” two suggest a “Moderate Buy,” and three suggest a “Hold.” IQV’s average analyst price target is $224, indicating an upside of 8.2% from the current levels. On the date of publication, Aritra Gangopadhyay did not have (either directly or indirectly) positions in any of the s...

Over the last six months, IQVIA’s shares have sunk to $177.52, producing a disappointing 19.8% loss - a stark contrast to the S&P 500’s 12.4% gain. This might have investors contemplating their next move. Is there a buying opportunity in IQVIA, or does it present a risk to your portfolio? Check out our in-depth research report to see what our analysts have to say, it’s free. Even though the stock has become cheaper, we’re swiping left on IQVIA for now. Here are three reasons why there are better opportunities than IQV, plus one stock we’d rather own. A company’s long-term sales performance is one signal of its overall quality. Any business can put up a good quarter or two, but many enduring ones grow for years. Unfortunately, IQVIA’s 6.7% annualized revenue growth over the last five years was mediocre. This fell short of our benchmark for the healthcare sector. We can better understand Drug Development Inputs & Services companies by analyzing their constant currency revenue. This metric excludes currency movements, which are outside of IQVIA’s control and are not indicative of underlying demand. Over the last two years, IQVIA’s constant currency revenue averaged 4.5% year-on-year growth. This performance slightly lagged the sector and suggests it might have to lower prices or invest in product improvements to accelerate growth, factors that can hinder near-term profitability. If you’ve followed StockStory for a while, you know we emphasize free cash flow. Why, you ask? We believe that in the end, cash is king, and you can’t use accounting profits to pay the bills. As you can see below, IQVIA’s margin was unchanged over the last five years, showing it couldn’t improve. Its free cash flow margin for the trailing 12 months was 12.7%. IQVIA’s business quality ultimately falls short of our standards. After the recent drawdown, the stock trades at 13.6× forward P/E (or $177.52 per share). This valuation is reasonable, but the company’s shakier fundamentals present too much downside risk. We’re pretty confident there are more exciting stocks to buy at the moment. We’d recommend looking at a safe-and-steady industrials business benefiting from an upgrade cycle. ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They re...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at IQVIA (NYSE:IQV) and the best and worst performers in the drug development inputs & services industry. Companies specializing in drug development inputs and services play a crucial role in the pharmaceutical and biotechnology value chain. Essential support for drug discovery, preclinical testing, and manufacturing means stable demand, as pharmaceutical companies often outsource non-core functions with medium to long-term contracts. However, the business model faces high capital requirements, customer concentration, and vulnerability to shifts in biopharma R&D budgets or regulatory frameworks. Looking ahead, the industry will likely enjoy tailwinds such as increasing investment in biologics, cell and gene therapies, and advancements in precision medicine, which drive demand for sophisticated tools and services. There is a growing trend of outsourcing in drug development for nimbleness and cost efficiency, which benefits the industry. On the flip side, potential headwinds include pricing pressures as efforts to contain healthcare costs are always top of mind. An evolving regulatory backdrop could also slow innovation or client activity. The 8 drug development inputs & services stocks we track reported a satisfactory Q1. As a group, revenues beat analysts’ consensus estimates by 1.6% while next quarter’s revenue guidance was in line. Thankfully, share prices of the companies have been resilient as they are up 9.3% on average since the latest earnings results. Created from the 2016 merger of Quintiles (a clinical research organization) and IMS Health (a healthcare data specialist), IQVIA (NYSE:IQV) provides clinical research services, data analytics, and technology solutions to help pharmaceutical companies develop and market medications more effectively. IQVIA reported revenues of $4.15 billion, up 8.4% year on year. This print exceeded analysts’ expectations by 1.1%. Overall, it was a satisfactory quarter for the company with a narrow beat of analysts’ revenue estimates and full-year EBITDA guidance meeting analysts’ expectations. "IQVIA delivered an outstanding start to the year, with organic revenue growth accelerating more than anticipated, Adjusted Diluted EPS exceeding the high-end of our expectations...

It has been about a month since the last earnings report for Penumbra (PEN). Shares have lost about 1.2% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Penumbra due for a breakout? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent catalysts for Penumbra, Inc. before we dive into how investors and analysts have reacted as of late. Penumbra reported first-quarter 2026 earnings per share (EPS) of 82 cents, a penny lower than the year-ago quarter. The figure missed the Zacks Consensus Estimate by 26.1%. Penumbra registered revenues of $374.8 million in the reported quarter, up 15.6% year over year. The figure topped the Zacks Consensus Estimate by 1.4%. In the reported quarter, Penumbra’s gross profit improved 17.4% year over year to $253.4 million. The gross margin expanded 102 basis points (bps) to 67.6% despite a 12.1% rise in the cost of revenues. Selling, general and administrative expenses rose 25.6% to $192.8 million. Research and development expenses totaled $22.4 million, up 1.4% year over year. Operating profit amounted to $38.2 million compared with $40.4 million in the corresponding period of 2025. The adjusted operating margin contracted 225 bps year over year to 10.2%. Penumbra exited the first quarter of 2026 with cash and marketable investments of $615.7 million compared with $544.8 million at the end of 2025. Analysts were quiet during the last two month period as none of them issued any earnings estimate revisions. Currently, Penumbra has a great Growth Score of A, though it is lagging a lot on the Momentum Score front with an F. Charting a somewhat similar path, the stock has a score of D on the value side, putting it in the bottom 40% for this investment strategy. Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in. Penumbra has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months. Penumbra belongs to the Zacks Medical - Instruments industry. Another stock from the same industry, IQVIA Holdings (IQV), has gained 4.6% over the past month. More than a month has passed since the company reported results for the quarter ended March 2026. IQVIA reported revenues of $4.15...

ICON plc ICLR is moving through a credibility and earnings reset that is now as much about controls as it is about demand. The company has laid out the scope of its accounting findings, flagged material weaknesses, and set expectations for a down year in 2026. With profitability showing heightened sensitivity to mix and estimates, investors are likely to focus on execution and consistency. ICON currently carries a Zacks Rank #5 (Strong Sell). ICON’s Audit Committee review concluded that improper adjustments were made to clinical trial services revenue from third-quarter 2023 through fourth-quarter 2024. The issue primarily impacted the timing of revenue recognition, rather than the underlying business activity. The company disclosed the findings resulted in an overstatement of full-year revenue of $65 million in 2023 and $93 million in 2024. Beyond the revenue timing, the review also cited errors tied to cost-to-complete estimates, realizable value assessments, and certain manual adjustments that extended into 2025. In the past year, ICLR shares have surged 9.9% against the industry’s 3.2% decline. Image Source: Zacks Investment Research For investors, the timing element matters because it goes to the reliability of reported trend lines. When revenue is shifted across periods, it can distort growth comparisons, backlog conversion assumptions, and margin expectations that are built from quarterly patterns. Alongside the investigation findings, ICON identified material weaknesses in internal controls over financial reporting. The company cited gaps in both entity-level controls and controls over revenues and related accounts, which raises the bar for proving that the process is now repeatable and durable. Management is implementing a remediation plan that includes organizational changes, revised policies and procedures, additional training, and tighter controls over manual adjustments. The direction is clear: reduce discretion, improve oversight, and standardize how revenue-related judgments are made and reviewed. The confidence overhang is the timeline. Management has signaled that fully embedding remediation across 2026 remains a key risk for investor confidence, which can keep valuation and sentiment capped even if operating metrics begin to stabilize. Fourth-quarter 2025 results highlighted how quickly profitability can swing when mix and estimates move to...

It has been about a month since the last earnings report for IQVIA Holdings (IQV). Shares have added about 3.2% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is IQVIA due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. IQVIA Holdings reported impressive first-quarter 2026 results, wherein earnings and revenues beat the Zacks Consensus Estimate. IQV has posted first-quarter 2026 adjusted earnings of $2.90 per share, beating the Zacks Consensus Estimate of $2.83 by 2.5%. Revenues came in at $4.15 billion, topping the consensus mark of $4.08 billion by 1.6%. Results improved year over year, with adjusted diluted earnings per share up 7.4% and revenues rising 8.4%. The quarter benefited from better-than-expected organic growth across the business, supported by strengthening demand indicators, including a $34.2-billion contracted backlog in the Research & Development Solutions business. Commercial Solutions delivered the sharpest top-line momentum in the quarter. Segmental revenues were $1.75 billion, increasing 11.6% on a reported basis and 8.5% at constant currency. Management highlighted notable strength across patient solutions, analytics and consulting, and commercial engagement services. The company also pointed to growing traction in AI-enabled offerings, suggesting product innovation is contributing to sales performance alongside broader market demand. Research & Development Solutions revenues were $2.40 billion, up 6.2% on a reported basis and 4.2% at constant currency. Excluding reimbursed expenses, R&D Solutions revenues increased 6.6% reported, reflecting healthier underlying service growth. Beyond reported revenues, the bookings picture remained constructive. Net new bookings were $2.5 billion, with a first-quarter book-to-bill ratio of 1.04X and a trailing-12-month ratio of 1.11X. The company also expects $8.9 billion of contracted work to convert into revenues over the next 12 months, indicating 7.6% year-over-year growth, offering a clearer line of sight into near-term demand. Profitability remained solid in the quarter, with adjusted EBITDA of $932 million, up 5.5% year over year. GAAP net income attributab...

IQVIA’s first quarter results were positively received by the market, reflecting stronger-than-expected revenue growth and solid execution in both its Commercial and R&D Solutions segments. Management attributed this outperformance to increased client demand across core offerings, particularly in areas integrating artificial intelligence and analytics. CEO Ari Bousbib highlighted that, “our organic revenue growth rate in Commercial Solutions doubled, and our organic revenue growth rate in R&D Solutions tripled,” compared to a year ago, with notable momentum in Patient Solutions and Analytics and Consulting. The company’s ability to secure large, multiyear contracts with leading pharmaceutical clients and to embed AI across business lines were key factors supporting robust top and bottom line performance. Is now the time to buy IQV? Find out in our full research report (it’s free). Revenue: $4.15 billion vs analyst estimates of $4.10 billion (8.4% year-on-year growth, 1.1% beat) Adjusted EPS: $2.90 vs analyst estimates of $2.82 (3% beat) Adjusted EBITDA: $932 million vs analyst estimates of $926.4 million (22.5% margin, 0.6% beat) The company reconfirmed its revenue guidance for the full year of $17.25 billion at the midpoint Management slightly raised its full-year Adjusted EPS guidance to $12.80 at the midpoint EBITDA guidance for the full year is $4 billion at the midpoint, in line with analyst expectations Operating Margin: 12.4%, in line with the same quarter last year Constant Currency Revenue rose 6% year on year (3.5% in the same quarter last year) Market Capitalization: $28.97 billion While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Leerink Partners asked how the mix shift toward full-service bookings versus pass-throughs would affect future margins. CEO Ari Bousbib clarified that pass-throughs have no profit impact and that recent booking mix was a one-off event, not a new trend. Justin Bowers (Deutsche Bank) questioned if the change in booking mix signals a shift in client strategy or affects margin outlook. Bousbib reiterated that the mix was driven by specific trial types this quarter, not a broader shift...

Interested in IQVIA Holdings Inc.? Here are five stocks we like better. IQVIA posted record Q1 2026 results, with revenue of $4.151 billion and adjusted diluted EPS of $2.90, both above the high end of guidance. Management said growth accelerated in both Commercial Solutions and R&D Solutions. R&D demand and backlog remained strong, with net new bookings of $2.5 billion and backlog hitting a record $34.2 billion. Management said the clinical development pipeline and emerging biopharma activity continue to support future growth. The company is leaning heavily into AI, highlighting 192 deployed AI agents and the launch of IQVIA.ai, while saying AI is increasing client demand rather than reducing it. IQVIA also reaffirmed full-year revenue and EBITDA guidance and raised its adjusted EPS outlook. Beyond Biotech—3 Healthcare Stocks for Growth-Minded Investors IQVIA (NYSE:IQV) reported record first-quarter revenue and adjusted diluted earnings per share for 2026, with management citing accelerating organic growth across its Commercial Solutions and R&D Solutions businesses, increased demand tied to artificial intelligence offerings and continued strength in forward-looking clinical development metrics. Chairman and Chief Executive Officer Ari Bousbib said the company’s first-quarter revenue and adjusted diluted EPS exceeded the high end of guidance, reflecting “solid top and bottom-line performance.” He said organic revenue growth doubled year over year in Commercial Solutions and tripled in R&D Solutions. → Beyond NVIDIA: Picks-and-Shovels AI Plays with Strong Momentum Total first-quarter revenue was $4.151 billion, up 8.4% on a reported basis and 6.0% at constant currency, Executive Vice President and Chief Financial Officer Mike Fedock said. Adjusted EBITDA rose 5.5% to $932 million. GAAP net income was $274 million, or $1.61 per diluted share, while adjusted net income was $492 million. Adjusted diluted EPS was $2.90, up 7.4% year over year. Commercial Solutions revenue was $1.754 billion in the quarter, up 11.6% on a reported basis and 8.5% at constant currency. Bousbib said organic growth in the segment was 5%, compared with about 2.5% in the prior-year period. → 3 Ways to Target the Resources Powering AI and Data Centers He attributed the improvement to continued product launches by clients, increased use of IQVIA services and strength in several areas, inc...

Clean Harbors, Inc. CLH reported mixed first-quarter 2026 results. Earnings per share (EPS) beat the Zacks Consensus Estimate, while revenues missed the same. The earnings beat failed to impress the market, as the stock has dipped 6.9% since the release of results on May 6. CLH posted first-quarter of 2026 earnings of $1.19 per share, beating the Zacks Consensus Estimate of $1.15 by 3.5%. Revenues came in at $1.46 billion, missing the consensus mark of $1.47 billion by 0.4%. Earnings grew 9.2% year over year, while revenues increased 1.9%. Management highlighted stronger profitability in both operating segments, supported by disciplined pricing and a late-quarter lift in base oil pricing, alongside a record-low Total Recordable Incident Rate (TRIR) of 0.39. Clean Harbors, Inc. price-consensus-eps-surprise-chart | Clean Harbors, Inc. Quote Clean Harbors described the quarter as better than expected, with higher profitability across both operating segments despite weather-related disruptions that weighed on parts of the collection and services business in February. Management also pointed to continued momentum exiting the quarter, framing the operating backdrop as supportive for its disposal and recycling network, with added tailwinds from project services and PFAS-related opportunities. Environmental Services generated first-quarter revenues of $1.24 billion, up 2.9% from the year-ago quarter. The company attributed growth to project services, including PFAS-related work and emergency response activity, while citing healthy demand for disposal and recycling services. Operationally, the company reported Technical Services revenue growth of 5% and Safety-Kleen Environmental Services revenue growth of 7%, aided by pricing and higher volumes. Incineration utilization, including the Kimball incinerator, was 80% versus 81% a year ago, reflecting planned maintenance days and weather impacts. Landfill volumes increased 34% and Field Services revenues rose 7%, including a large-scale emergency event that generated approximately $10 million in revenues. Safety-Kleen Sustainability Solutions posted revenues of $217.1 million, down 3.4% year over year, as lower market pricing for base and blended products outweighed other benefits. Management said that the revenue decline was expected, and noted that base oil prices strengthened late in the quarter. Even with the softer...

Republic Services, Inc. RSG delivered solid first-quarter 2026 results, with earnings per share of $1.70 beating the Zacks Consensus Estimate of $1.64 by 3.7%. Earnings increased 7.6% from $1.58 in the year-ago quarter. Revenues rose 2.6% year over year to $4.11 billion and edged past the consensus mark of $4.10 billion. Disciplined pricing and cost management supported profitability, as the adjusted EBITDA margin expanded 50 basis points to 32.1%. Republic Services, Inc. price-consensus-eps-surprise-chart | Republic Services, Inc. Quote Republic Services’ internal growth leaned heavily on price in the quarter. Core price on total revenues increased 5.7%, reflecting continued traction in open market pricing and restricted pricing, even as fuel recovery fees provided only a modest lift. Volume remained a headwind, with total revenues declining 0.8% on volume, while average yield added 3.4%. Management noted that severe weather weighed on activity during the quarter, but pointed to sequential improvement in several verticals, including landfill and container-related lines. Collection remained the largest contributor, generating $2.84 billion in revenues in the first quarter. Within the broader portfolio, small-container revenues rose to $1.31 billion, while large-container revenues came in at $768 million and residential revenues totaled $747 million, underscoring the scale of the core business. Transfer revenues (net) increased to $200 million and landfill revenues (net) rose to $453 million. Environmental solutions revenues (net) declined to $405 million, while “other” revenues increased to $217 million, led by recycling processing and commodity sales of $112 million alongside other non-core revenues. Profitability improved across the consolidated model, supported by cost-control and underlying operating leverage. Net income was $525 million, translating to a net income margin of 12.8%, up from 12.3% a year ago. On an adjusted basis, RSG reported $1.32 billion of adjusted EBITDA. By business type, Recycling & Waste produced adjusted EBITDA of $1.24 billion and an adjusted EBITDA margin of 33.6% compared with 33% in the prior-year quarter. Environmental Solutions generated adjusted EBITDA of $78 million with a margin of 19.2%, down from 20.8% last year, reflecting the year-over-year revenue decline in that business. RSG’s cash generation was a notable feature...